![](/wp-content/uploads/2020/10/Abbott-Novo-Chungai-Announcement.png)
$599
Abbott Q3 ’20 Earnings Update; Novo Licenses Antibody Engineering Tech From Chugai
Two diabetes-related news items have been observed: Abbott hosted its Q3 ’20 earnings call (press release) and Chugai licensed its antibody engineering technology to Novo Nordisk (press release). Below, FENIX provides highlights from the respective news items as well as insight into how Novo may leverage Chugai’s antibody technology.